Jordyn Sava

Benmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.

EBC-129 was well tolerated, with a safety profile consistent with other MMAE-based ADCs in patients with PDAC and other solid tumors.

Cisplatin, nab-paclitaxel, gemcitabine, and capecitabine significantly improved EFS vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.

Anakinra prophylaxis did not significantly decrease the incidence or severity of CRS or ICANS in patients with LBCL treated with liso-cel.

The TALAPRO-2 trial revealed promising survival data for patients with metastatic CRPC treated with talazoparib and enzalutamide.

Nivolumab plus ipilimumab generated an ORR of 36% vs 13% from levantinib plus sorafenib in unresectable hepatocellular carcinoma in the CheckMate 9DW study.

Data shown at ASH 2024 demonstrated higher OS rates with anti-CD20 antibodies in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Data from KEYNOTE-522 show improved efficacy with pembrolizumab/chemotherapy across subgroups of patients with TNBC.

In patients with lens-refractory multiple myeloma, cilta-cel generated deeper minimal residual disease rates across all patient subgroups.

Phase 3 data show meaningful benefits with uproleselan in patients with primary refractory AML and post-transplant survival.

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Phase 3 data also show an improvement in deterioration-free survival with TTFields and best supportive care in those with NSCLC and brain metastases.

Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.

Treatment with cretostimogene grenadenorepvec appears tolerable among patients with high-risk BCG–unresponsive NMIBC in the phase 3 BOND-003 trial.

Data from the TRANSCEND NHL 001 trial suggest a favorable benefit/risk profile for lisocabtagene maraleucel in mantle cell lymphoma with high-risk disease features.

Treatment with belzutifan increased the time to disease progression, according to findings from the LITESPARK-005 trial.

Results from the phase 3 CheckMate-8HW trial highlight that the safety of frontline nivolumab plus ipilimumab in microsatellite instability–high or mismatch repair deficient is comparable with prior reports.

Pembrolizumab plus lenvatinib yields clinically relevant efficacy in clear cell renal cell carcinoma subgroups based on site of metastasis and number of metastatic sites in the phase 3 CLEAR trial.

Data suggest a role for TIGIT blockade or CD25-positive cell depletion to enhance teclistamab’s efficacy in relapsed/refractory multiple myeloma.

Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.

Lenvatinib yields survival benefit in hepatocellular carcinoma following progression on immunotherapy.

In patients with non-germinal center B cell–like diffuse large B-cell lymphoma, the combination of orelabrutinib plus R-CHOP revealed an overall response rate of 86.4%.

Abemaciclib prolonged overall survival when added to a nonsteroidal aromatase inhibitor in hormone receptor–positive, HER2–negative breast cancer, according to updated findings from the MONARCH 3 trial presented at 2022 ESMO.

Results from the phase 2 PEMMELA trial revealed positive treatment benefits in patients with malignant pleural mesothelioma who were given pembrolizumab plus lenvatinib.

Across 3 clinical trials, investigators continued to observe durable responses with larotrectinib, which showed the importance of NTRK gene fusion testing in patients with various cancer types.

Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.

The JAVELIN Bladder 100 trial demonstrated that avelumab plus best supportive care prolonged overall survival vs best supportive care alone for patients with advanced urothelial carcinoma.

Results of a phase 3 trial comparing neoadjuvant nivolumab plus chemotherapy denoted benefit vs chemotherapy alone for patients with resectable non-small cell lung cancer.

Children and young adults with H3K27M-positive diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas saw a clinical benefit when treated with GD2-directed chimeric antigen receptor T cell therapy.